Augmentation of TNF-induced osteoclast differentiation by inhibition of ERK and activation of p38: Similar intracellular signaling between RANKL- and TNF-induced osteoclast differentiation

Orthodontic Waves

Volumn 67, Issue 4, 2008, Pages 150-156

  Inami, Kaoru ^a   Sawai, Hirofumi ^a   Yakushiji, Kentaro ^a   Katao, Yuko ^a   Matsumoto, Naoyuki ^a   Domae, Naochika ^a  

^a OSAKA DENTAL UNIVERSITY   (Japan)

Author keywords

ERK; Osteoclast differentiation; p38; RANKL; TNF

Indexed keywords

EID: 54149097922     PISSN: 13440241     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.odw.2008.04.003     Document Type: Article

References (18)

1. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
2. Teitelbaum S.L. Osteoclasts: what do they do and how do they do it?. Am J Pathol 170 (2007) 427-435
3. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
4. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 (1998) 3597-3602
5. Takahashi N., Udagawa N., and Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256 (1999) 449-455
6. Tanaka S., Nakamura K., Takahasi N., and Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208 (2005) 30-49
7. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Gene Dev 13 (1999) 2412-2424
8. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
9. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
10. Matsumoto M., Sudo T., Saito T., Osada H., and Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 275 (2000) 31155-31161
11. Hotokezaka H., Sakai E., Kanaoka K., Saito K., Matsuo K., Kitaura H., et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277 (2002) 47366-47372
12. Azuma Y., Kaji K., Katogi R., Takeshita S., and Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275 (2000) 4858-4864
13. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191 (2000) 275-286
14. Matsumoto M., Sudo T., Maruyama M., Osada H., and Tsujimoto M. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 486 (2000) 23-28
15. Woo J.T., Nakagawa H., Krecic A.M., Nagai K., Hamilton A.D., Sebti S.M., et al. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NFκB ligand (RANKL) or tumor necrosis factor-α (TNF-α). Biochem Pharmacol 69 (2005) 87-95
16. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 (1999) 3540-3545
17. Kumar S., Jiang M.S., Adams J.L., and Lee J.C. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 263 (1999) 825-831
18. Ge B., Gram H., Di Padova F., Huang B., New L., Ulevitch R.J., et al. MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α. Science 295 (2002) 1291-1294